<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="92693"><DrugName>DTX-301</DrugName><DrugSynonyms><Name><Value>AAV based gene therapy (undisclosed rare genetic diseases), Dimension</Value></Name><Name><Value>AAV based gene therapy (ornithine transcarbamylase deficiency), Dimension Therapeutics</Value></Name><Name><Value>AAV OTC (ornithine transcarbamylase deficiency), Dimension Therapeutics</Value></Name><Name><Value>DTX-301</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AAV8-OTC gene therapy (ornithine transcarbamylase deficiency), Dimension Therapeutics</Value></Name><Name><Value>scAAV8OTC</Value></Name><Name><Value>AAV OTC (ornithine transcarbamylase deficiency), Ultragenyx Pharmaceutical</Value></Name><Name><Value>AAV8-OTC gene therapy (intravenous, ornithine transcarbamylase deficiency), Ultragenyx Pharmceutical</Value></Name></DrugSynonyms><CompanyOriginator id="1089633">Dimension Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="1062138">Ultragenyx Pharmaceutical Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1089633">Dimension Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1062138" type="Company"><TargetEntity id="5035304895" type="organizationId">Ultragenyx Pharmaceutical Inc</TargetEntity></SourceEntity><SourceEntity id="1089633" type="Company"><TargetEntity id="5040275565" type="organizationId">Dimension Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1820" type="ciIndication"><TargetEntity id="10052450" type="MEDDRA"/><TargetEntity id="D020163" type="MeSH"/><TargetEntity id="664" type="ORPHANET"/><TargetEntity id="-1633074271" type="omicsDisease"/><TargetEntity id="4511" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1820">Ornithine transcarbamylase deficiency</Indication></IndicationsPrimary><ActionsPrimary><Action id="36959">OTC gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4781">Adeno-associated virus based gene therapy</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="62">Virus recombinant</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology></Technologies><LastModificationDate>2019-05-24T19:35:02.000Z</LastModificationDate><ChangeDateLast>2019-05-27T00:00:00.000Z</ChangeDateLast><AddedDate>2014-09-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1062138" linkType="Company"&gt;Ultragenyx Pharmaceutical&lt;/ulink&gt;, following the acquisition of &lt;ulink linkID="1089633" linkType="Company"&gt;Dimension Therapeutics&lt;/ulink&gt;, is developing DTX-301 (AAV OTC; scAAV8OTC), an adeno-associated virus 8 (AAV8)-based vector gene therapy that delivers human ornithine transcarbamylase (OTC), using  &lt;ulink linkID="1054635" linkType="Company"&gt;RegenX&lt;/ulink&gt;'s (now REGENXBIO) NAV vector technology, for the potential liver-directed treatment of OTC deficiency [&lt;ulink linkID="1572500" linkType="Reference"&gt;1572500&lt;/ulink&gt;], [&lt;ulink linkID="1891623" linkType="Reference"&gt;1891623&lt;/ulink&gt;], [&lt;ulink linkID="1979900" linkType="Reference"&gt;1979900&lt;/ulink&gt;], [&lt;ulink linkID="1978961" linkType="Reference"&gt;1978961&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2016, a phase I/II trial was initiated [&lt;ulink linkID="1891623" linkType="Reference"&gt;1891623&lt;/ulink&gt;]; in September 2018, positive data from the second cohort of the trial were reported, and enrollment into the third and final cohort of the trial was expected at the end of 2018 [&lt;ulink linkID="2077069" linkType="Reference"&gt;2077069&lt;/ulink&gt;]. In April 2019, one subject was enrolled  in the third cohort [&lt;ulink linkID="2146565" linkType="Reference"&gt;2146565&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2019, Ultragenyx noted that the company had in-licensed patents and patent applications owned by the &lt;ulink linkID="20658" linkType="Company"&gt;University of Pennsylvania&lt;/ulink&gt; (UPENN), which are  licensed or sublicensed by REGENXBIO and sublicensed to Ultragenyx, relating to various AAVs and vectors using the capsids of those viruses. In-licensed patents relating to the AAV8 capsid were slated to expire between 2022 and 2024 in the US, and in 2022 in foreign countries. Additionally, an in-licensed pending application in the US and corresponding pending foreign patent applications directed toward the codon-optimized version of the OTC gene used in DTX-301 were  anticipated to expire in 2035 (without patent term extension), if granted [&lt;ulink linkID="2121713" linkType="Reference"&gt;2121713&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2015, the FDA granted Orphan designation for OTC deficiency [&lt;ulink linkID="1725229" linkType="Reference"&gt;1725229&lt;/ulink&gt;], [&lt;ulink linkID="1725476" linkType="Reference"&gt;1725476&lt;/ulink&gt;]. In June 2017, the company was granted Fast Track Designation for OTC deficiency [&lt;ulink linkID="1941410" linkType="Reference"&gt;1941410&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2016, the EMA's COMP recommended granting Orphan status for OTC deficiency [&lt;ulink linkID="1738218" linkType="Reference"&gt;1738218&lt;/ulink&gt;]; in March 2016, the Orphan designation was granted [&lt;ulink linkID="1749169" linkType="Reference"&gt;1749169&lt;/ulink&gt;]. In June 2017, the company was granted Fast Track Designation for OTC deficiency [&lt;ulink linkID="1941410" linkType="Reference"&gt;1941410&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2018, an observational, long-term follow-up study enrolling by invitation (&lt;ulink linkID="350539" linkType="Protocol"&gt;NCT03636438&lt;/ulink&gt;; 301OTC02; 2018-000156-18; CAPtivate) was initiated in Spain and UK to evaluate safety and efficacy of the therapy in adults (expected n = 12) with late-onset OTC deficiency. The primary endpoint was to determine the number of participants with adverse events and serious adverse events for the time frame of up to 260 weeks following dtx301 administration. At that time, the study was expected to complete in December 2024 [&lt;ulink linkID="2108132" linkType="Reference"&gt;2108132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) had approved a phase  I/II  study for the treatment of  OTC deficiency  [&lt;ulink linkID="1775161" linkType="Reference"&gt;1775161&lt;/ulink&gt;]. In December 2016, the  FDA accepted an IND application for DTX-301 in the treatment of OTC deficiency [&lt;ulink linkID="1884809" linkType="Reference"&gt;1884809&lt;/ulink&gt;]. Later that month, the open-label, dose-finding, safety, phase I/II study (&lt;ulink linkID="263990" linkType="Protocol"&gt;NCT02991144&lt;/ulink&gt;; 301OTC01;  2016-001057-40; CAPtivate) of single ascending doses of DTX-301 in adults (expected n = 9) with late-onset OTC deficiency, was initiated in the US. The study was to complete in November 2018 [&lt;ulink linkID="1891623" linkType="Reference"&gt;1891623&lt;/ulink&gt;]. In June 2017, the trial was initiated in Spain and included the assessment of 13C-acetate to evaluate rate of ureagenesis and hepatocyte (liver) ureagenesis capacity  [&lt;ulink linkID="1941410" linkType="Reference"&gt;1941410&lt;/ulink&gt;]. In July 2017, the trial was initiated in the UK and Canada [&lt;ulink linkID="1891623" linkType="Reference"&gt;1891623&lt;/ulink&gt;]. In August 2017,  patient dosing was initiated  [&lt;ulink linkID="1957964" linkType="Reference"&gt;1957964&lt;/ulink&gt;]. In November 2017, patient dosing was completed in the first cohort of three patients enrolled in the phase I/II trial. Patients in the first cohort received a single dose of 2.0 into 10 10^12  GC/kg.  Initial data from the first cohort of three patients were expected in early 2018 [&lt;ulink linkID="1983283" linkType="Reference"&gt;1983283&lt;/ulink&gt;]. In January 2018, interim safety and efficacy data were reported. In one patient, the rate of ureagenesis was normalized and maintained over 12 weeks; at 12 weeks, the rate of ureagenesis was 261 umol/kg/hr, which represented a 30% increase from baseline. A second patient did not show a clinically meaningful change in rate of ureagenesis over the 12-week period, while a modest increase in ureagenesis was observed in a third patient at 6 weeks. The drug was safe and well tolerated with no serious adverse events reported [&lt;ulink linkID="1995638" linkType="Reference"&gt;1995638&lt;/ulink&gt;]. In March 2018, longer-term safety and efficacy data from the first cohort were reported, showing that one  patient had maintained and substantially increased ureagenesis levels through 24 weeks. At that time, the company planned to initiate the second cohort with a single DTX-301 dose of 6.0 × 10^12 GC/kg in three patients later in March 2018  [&lt;ulink linkID="2011495" linkType="Reference"&gt;2011495&lt;/ulink&gt;]. In September 2018, further data at the 2e12 GC/kg dose were presented at the 2018 SSIEM Annual Symposium in Athens, Greece. Infusion-related events were not reported. The patient with normalized ureagenesis rate sustained &amp;gt; 24-weeks post-dose also discontinued ammonia scavenger medications [&lt;ulink linkID="2068442" linkType="Reference"&gt;2068442&lt;/ulink&gt;]. In September 2018,  topline data from the second dose cohort and  longer-term data from the first dose cohort were reported. Data from the second cohort demonstrated normalization of ureagenesis to 104% at week 24 in first patient, and the drug was safe. At week 52, cohort one responder demonstrated continued biochemical improvement and clinical stability. At that time, the DMC recommended initiation of third dose cohort on review of second cohort data. Enrollment (n = 3) in third cohort (1.0 × 10^13 GC/kg dose) was to begin later that year and data were expected in mid-2019 [&lt;ulink linkID="2077069" linkType="Reference"&gt;2077069&lt;/ulink&gt;]. In October 2018, cohort 1 data were presented at the XXVI ESGCT Congress in Lausanne, Switzerland. Serious adverse events were not reported [&lt;ulink linkID="2112017" linkType="Reference"&gt;2112017&lt;/ulink&gt;]. In February 2019, enrollment in the third cohort was underway. At that time,  data were expected in mid-2019 [&lt;ulink linkID="2121104" linkType="Reference"&gt;2121104&lt;/ulink&gt;]. By May 2019, data from two responders in cohort 1 and 2 demonstrated maintenance of ureagenesis levels above normal in week 52 and 78 [&lt;ulink linkID="2148435" linkType="Reference"&gt;2148435&lt;/ulink&gt;]. In April 2019, further results were presented at the 2019 ASGCT Annual Meeting in Washington DC. All adverse events (AEs) were grade 1 to 2. A total of two patients experienced mild, asymptomatic ALT increases that were resolved with corticosteroids, per protocol. Following review of cohort 2 data, one subject was enrolled at a dose of 1x10 (13) GC/kg (cohort 3) [&lt;ulink linkID="2146565" linkType="Reference"&gt;2146565&lt;/ulink&gt;]. Later that month, further cohort 1 data of three patients were presented at the 2019 Annual Meeting of the Society for Inherited Metabolic Diseases in Washington DC. All reported adverse events were of grade 1 or 2 while no infusion-related or serious adverse events (primary endpoint) were reported. At 24 weeks post treatment, one patient achieved normalized ureagenesis rate which further increased at 52 weeks. This patient discontinued all ammonia scavenger medications and liberalized dietary protein restrictions [&lt;ulink linkID="2152709" linkType="Reference"&gt;2152709&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In April 2015, the company anticipated to enter IND-enabling studies during the next 12 to 18 months [&lt;ulink linkID="1652916" linkType="Reference"&gt;1652916&lt;/ulink&gt;]; later that month, the company planned for a clinical trials in 2016 [&lt;ulink linkID="1653820" linkType="Reference"&gt;1653820&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By June 2016, preclinical data were reported. DTX-301 had the potential to be a well-tolerated, effective therapy for OTC deficiency. At that time, IND-enabling studies had been completed [&lt;ulink linkID="1775161" linkType="Reference"&gt;1775161&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1062138">Ultragenyx Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978961" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062138">Ultragenyx Pharmaceutical Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978961" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062138">Ultragenyx Pharmaceutical Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978961" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062138">Ultragenyx Pharmaceutical Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1978961" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2014-06-24T00:00:00.000Z</StatusDate><Source id="1572500" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate><Source id="1738218" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-06-27T00:00:00.000Z</StatusDate><Source id="1941410" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1891623" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-07-20T00:00:00.000Z</StatusDate><Source id="1891623" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1089633">Dimension Therapeutics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate>2017-07-20T00:00:00.000Z</StatusDate><Source id="1891623" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1089633">Dimension Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-06-27T00:00:00.000Z</MileStoneDate><Source id="1941410" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1089633">Dimension Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-06-27T00:00:00.000Z</MileStoneDate><Source id="1941410" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1089633">Dimension Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-03-21T00:00:00.000Z</MileStoneDate><Source id="1749169" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1089633">Dimension Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-02-18T00:00:00.000Z</MileStoneDate><Source id="1738218" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1089633">Dimension Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-12-29T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-01459"><Name>OTC gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2152709" linkType="reference" linkID="2152709"&gt;2152709&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2146565" linkType="reference" linkID="2146565"&gt;2146565&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>